Could a common blood pressure drug slow type 1 diabetes?
NCT ID NCT04545151
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether verapamil, a drug usually used for high blood pressure, can help preserve insulin-making cells in adults newly diagnosed with type 1 diabetes. 136 participants received either verapamil or a placebo for 12 months. The main goal was to see if verapamil could maintain the body's ability to produce insulin, measured by a C-peptide test.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Verapamil SR (a blood pressure medication)
What this could lead to
If it works, this could point toward a way to preserve insulin production in people newly diagnosed with type 1 diabetes, potentially slowing the disease.
What could go wrong
This is a phase 2 trial with only 136 participants, so results are preliminary. Verapamil is not a cure and may not meaningfully change long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrokes Hospital
Cambridge, United Kingdom
-
Bart's Hospital QMUL
London, United Kingdom
-
Guy's Hospital
London, United Kingdom
-
HKA Hannover
Hanover, Germany
-
Institut National de la Santé et de la Recherche Médicale
Paris, France
-
John Radcliffe Hospital
Oxford, United Kingdom
-
Katholieke Universiteit Leuven
Leuven, Belgium
-
Medical University of Graz, Department of Internal Medicine Division of Endocrinology and Metabolism
Graz, Styria, 8010, Austria
-
NHS Greater Glasgow and Clyde-Queen Elizabeth University Hospital, Department of Diabetes
Glasgow, United Kingdom
-
OCDEM, John Radcliffe Hospital
Oxford, United Kingdom
-
Queen Elizabeth Hospital
Birmingham, United Kingdom
-
Queens Medical Centre
Nottingham, United Kingdom
-
Royal Hallamshire Hospital
Sheffield, United Kingdom
-
Singleton Hospital
Swansea, United Kingdom
-
Southmead Hospital
Bristol, United Kingdom
-
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
-
Universitair Ziekenhuis Brussel
Brussels, Belgium
-
University Hospital of Wales
Cardiff, United Kingdom
-
Università Vita-Salute San Raffaele
Milan, Italy
-
Università degli Studi di Siena
Siena, Italy
-
Universität Ulm
Ulm, Germany
-
Université Libre de Bruxelles/ Hôpital Erasme
Brussels, Belgium